Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Ohhhh nooooo Ragers what’s up???

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Oct 10, 2024 1:30pm

92 Views

Post# 36261271

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Ohhhh nooooo Ragers what’s up???

Small biotechs rely on news to maintain any upward movement. The degree of market movement directly reflects to the news. We'll see if if ONC management have any additional releases to push this this to the next stage. The next scheduled release seems to be the financials November 1, 3 weeks away. Something next week will be required, otherwise there could be a small short attack. It would be nice for a change if management has ancipated this and have something of substance to release soon. A buyout would be nice.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles